Back to Journals » Drug Design, Development and Therapy » Volume 16
Corrigendum
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
4,167 | Dovepress* | 4,112+ | 88 | 4,200 | |
PubMed Central* | 55 | 45 | 100 | ||
Totals | 4,167 | 133 | 4,300 | ||
*Since 27 October 2022 |
View citations on PubMed and Google Scholar